Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®).

Literature DB >> 21861084

Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®).

Diamar Pardo-López, Ester Francés-Muñoz, Roberto Gallego-Pinazo, Manuel Díaz-Llopis.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 21861084 DOI： 10.1007/s00417-011-1802-x

Source DB: PubMed Journal: Graefes Arch Clin Exp Ophthalmol ISSN： 0721-832X Impact factor: 3.117

× No keyword cloud information.

4 in total

1. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema.

Authors: Andrew A Moshfeghi; Ingrid U Scott; Harry W Flynn; Carmen A Puliafito
Journal: Am J Ophthalmol Date: 2004-09 Impact factor: 5.258

2. Anterior chamber transit of triamcinolone after intravitreal injection.

Authors: José M Ruiz-Moreno; Javier A Montero; Alberto Artola; Stefano Barile
Journal: Arch Ophthalmol Date: 2005-01

3. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

Authors: Julia A Haller; Baruch D Kuppermann; Mark S Blumenkranz; George A Williams; David V Weinberg; Connie Chou; Scott M Whitcup
Journal: Arch Ophthalmol Date: 2010-03

4. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.

Authors: George A Williams; Julia A Haller; Baruch D Kuppermann; Mark S Blumenkranz; David V Weinberg; Connie Chou; Scott M Whitcup
Journal: Am J Ophthalmol Date: 2009-03-09 Impact factor: 5.258

4 in total

24 in total

Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®).

1. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema.

2. Anterior chamber transit of triamcinolone after intravitreal injection.

3. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

4. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.

1. Anterior vitreous displacement of the intravitreal dexamethasone implant (Ozurdex).

2. Local safety of repeated intravitreal Ozurdex.

3. Effect of dexamethasone intravitreal implant in a corneal graft rejection.

4. In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device.

5. New Drugs and New Posterior Delivery Methods in CME.

6. The clinical outcomes of surgical management of anterior chamber migration of a dexamethasone implant (Ozurdex®).

7. Anterior migration of dexamethasone implant in a pseudophakic patient with intact posterior capsule.

8. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study].

9. Scleral fixation of dexamethasone intravitreal implant (OZURDEX®) in a case of angle-supported lens implantation.

Review 10. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.